<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37534972</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7658</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Season>Jul-Dec</Season></PubDate></JournalIssue><Title>Expert opinion on investigational drugs</Title><ISOAbbreviation>Expert Opin Investig Drugs</ISOAbbreviation></Journal><ArticleTitle>Experimental drugs in randomized controlled trials for long-COVID: what's in the pipeline? A systematic and critical review.</ArticleTitle><Pagination><StartPage>655</StartPage><EndPage>667</EndPage><MedlinePgn>655-667</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13543784.2023.2242773</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Over three years have passed since the emergence of coronavirus disease 2019 (COVID-19), and yet the treatment for long-COVID, a post-COVID-19 syndrome, remains long overdue. Currently, there is no standardized treatment available for long-COVID, primarily due to the lack of funding for post-acute infection syndromes (PAIS). Nevertheless, the past few years have seen a renewed interest in long-COVID research, with billions of dollars allocated for this purpose. As a result, multiple randomized controlled trials (RCTs) have been funded in the quest to find an effective treatment for long-COVID.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="UNASSIGNED">This systematic review identified and evaluated the potential of current drug treatments for long-COVID, examining both completed and ongoing RCTs.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="UNASSIGNED">We identified four completed and 22 ongoing RCTs, investigating 22 unique drugs. However, most drugs were deemed to not have high potential for treating long-COVID, according to three pre-specified domains, a testament to the ordeal of treating long-COVID. Given that long-COVID is highly multifaceted with several proposed subtypes, treatments likely need to be tailored accordingly. Currently, rintatolimod appears to have modest to high potential for treating the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) subtype, LTY-100 and Treamid for pulmonary fibrosis subtype, and metformin for general long-COVID prevention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yong</LastName><ForeName>Shin Jie</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Subang Jaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halim</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halim</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, School of Science, Engineering and Environment, University of Salford, Greater Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ming</LastName><ForeName>Long Chiau</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Subang Jaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goh</LastName><ForeName>Khang Wen</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Faculty of Data Science and Information Technology, INTI International University, Nilai, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfaresi</LastName><ForeName>Mubarak</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2523-835X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Zayed Military Hospital, Abu Dhabi, United Arab Emirates.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AlShehail</LastName><ForeName>Bashayer M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0003-2372-9462</Identifier><AffiliationInfo><Affiliation>Pharmacy Practice Department, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Fares</LastName><ForeName>Mona A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-1472-0642</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alissa</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4045-0810</Identifier><AffiliationInfo><Affiliation>Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sulaiman</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1590-6203</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Section, Medical Specialties Department, King Fahad Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsalem</LastName><ForeName>Zainab</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-2650-2378</Identifier><AffiliationInfo><Affiliation>Department of Epidemic Diseases Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alwashmi</LastName><ForeName>Ameen S S</ForeName><Initials>ASS</Initials><Identifier Source="ORCID">0000-0002-7290-8945</Identifier><AffiliationInfo><Affiliation>Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khamis</LastName><ForeName>Faryal</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5107-921X</Identifier><AffiliationInfo><Affiliation>Infection Diseases Unit, Department of Internal Medicine, Royal Hospital, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Kaabi</LastName><ForeName>Nawal A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0002-7680-1141</Identifier><AffiliationInfo><Affiliation>College of Medicine and Health Science, Khalifa University, Abu Dhabi, United Arab Emirates.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albayat</LastName><ForeName>Hawra</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1320-9017</Identifier><AffiliationInfo><Affiliation>Infectious Disease Department, King Saud Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsheheri</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2915-361X</Identifier><AffiliationInfo><Affiliation>Infectious Disease Department, King Saud Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garout</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1317-1186</Identifier><AffiliationInfo><Affiliation>Department of Community Medicine and Health Care for Pilgrims, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsalman</LastName><ForeName>Jameela</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5500-9905</Identifier><AffiliationInfo><Affiliation>Infection Disease Unit, Department of Internal Medicine, Salmaniya Medical Complex, Ministry of Health, Kingdom of Bahrain, Manama, Bahrain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfaraj</LastName><ForeName>Amal H</ForeName><Initials>AH</Initials><Identifier Source="ORCID">0000-0002-8506-6310</Identifier><AffiliationInfo><Affiliation>Pediatric Department, Abqaiq General Hospital, First Eastern Health Cluster, Abqaiq, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhajri</LastName><ForeName>Mashael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9325-0281</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhama</LastName><ForeName>Kuldeep</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Pathology, ICAR-Indian Veterinary Research Institute (IVRI), Bareilly, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alburaiky</LastName><ForeName>Lamees M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-2826-8813</Identifier><AffiliationInfo><Affiliation>Pediatric Department, Safwa General Hospital, Eastern Health Cluster, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsanad</LastName><ForeName>Ahlam H</ForeName><Initials>AH</Initials><Identifier Source="ORCID">0009-0002-4778-6832</Identifier><AffiliationInfo><Affiliation>Neonatal Intensive Care Unit, Pediatrics Department, Maternity and Children Hospital, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AlShurbaji</LastName><ForeName>Abdelmunim T</ForeName><Initials>AT</Initials><Identifier Source="ORCID">0009-0006-2546-6028</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Philadelphia University, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabaan</LastName><ForeName>Ali A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-6774-9847</Identifier><AffiliationInfo><Affiliation>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Nutrition, The University of Haripur, Haripur, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Investig Drugs</MedlineTA><NlmUniqueID>9434197</NlmUniqueID><ISSNLinking>1354-3784</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>NPJ3B3A39Y</RegistryNumber><NameOfSubstance UI="C000723313">N,N'-bis(2-(1H-imidazol-2-yl)ethyl)pentanediamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015507" MajorTopicYN="N">Drugs, Investigational</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">drug</Keyword><Keyword MajorTopicYN="N">post-COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">randomized clinical trial</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>13</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>9</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37534972</ArticleId><ArticleId IdType="doi">10.1080/13543784.2023.2242773</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>